PLX Key Stats
- PLX July Options Begin Trading May 20
- PROTALIX BIOTHERAPEUTICS, INC. Financials May 17
- Protalix Bio gets vote of confidence May 14
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 9
- Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Confe... May 8
- Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc., I... May 1
- J.C. Penney Lands a Loan, Protalix Rides on Approval, and 3 Other Hot Stocks Apr 29
- UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of... Apr 29
- Protalix Says COFEPRIS, Public Health Institute of Chile Grant Approval to UPLYS... Apr 29
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Apr 29
PLX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Protalix BioTherapeutics is down 15.47% over the last year vs S&P 500 Total Return up 27.96%, Pfizer up 36.16%, and Peregrine Pharmaceuticals up 204.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for PLX
Pro Report PDF for PLX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download PLX Pro Report PDF
Pro Strategies Featuring PLX
Did Protalix BioTherapeutics make it into our Pro Portfolio Strategies?